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Abstract
Neuroblastoma is the most common extracranial tumor and a major cause of infant cancer mortality worldwide.
Despite its importance, little is known about its molecular mechanisms. A striking feature of this tumor is its clinical
heterogeneity. Possible outcomes range from aggressive invasion to other tissues, causing patient death, to
spontaneous disease regression or differentiation into benign ganglioneuromas. Several efforts have been made in
order to find tumor progression markers. In this work, we have reconstructed the neuroblastoma regulatory network
using an information-theoretic approach in order to find genes involved in tumor progression and that could be used
as outcome predictors or as therapeutic targets. We have queried the reconstructed neuroblastoma regulatory
network using an aggressive neuroblastoma metastasis gene signature in order to find its master regulators (MRs).
MRs expression profiles were then investigated in other neuroblastoma datasets so as to detect possible clinical
significance. Our analysis pointed MAX as one of the MRs of neuroblastoma progression. We have found that higher
MAX expression correlated with favorable patient outcomes. We have also found that MAX expression and protein
levels were increased during neuroblastoma SH-SY5Y cells differentiation. We propose that MAX is involved in
neuroblastoma progression, possibly increasing cell differentiation by means of regulating the availability of
MYC:MAX heterodimers. This mechanism is consistent with the results found in our SH-SY5Y differentiation protocol,
suggesting that MAX has a more central role in these cells differentiation than previously reported. Overexpression of
MAX has been identified as anti-tumorigenic in other works, but, to our knowledge, this is the first time that the link
between the expression of this gene and malignancy was verified under physiological conditions.
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Introduction
Neuroblastoma is the most common extra-cranial solid tumor
and one of the leading causes of cancer mortality in children
worldwide [1–4]. These tumors are originated from embryonic
elements of the neural crest and sympathetic nervous system,
usually developing in the adrenal glands, but also arising in
nervous tissues of the neck, thorax, abdomen, and pelvis. The
metastatic capacity of this type of cancer is notable, being able
of compromising almost any tissue in the human body [2,5].
Another distinguishing feature of this disease is its clinical
heterogeneity. The possible endpoints span from complete
remission to patient death, even with advanced multimodal
therapy [6]. Numerous efforts have been made in order to sort
neuroblastoma patients in separate risk groups, such as the
International Neuroblastoma Risk Group (INRG) staging
system [7], which is based on clinical factors and imaging
studies, and the Children’s Oncology Group (COG) risk
stratification schema, which complements the former with
molecular aspects. The molecular approaches for assessing
patient clinical outcome are made by detecting DNA copy
number alterations or by searching for more specific segmental
aberrations, such as chromosomes 11q loss and 17q gain
[8,9]. The most reliable molecular classifier, however, is the
amplification of the MYCN oncogene, which is linked to grim
prognosis in the majority of cases [10–12].
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Lower grade neuroblastoma patients can be treated with
surgical resection alone, and may even be subject to
spontaneous remission without any intervention. Patients with
metastatic MYCN amplified tumors have the highest mortality
rate and are usually unresponsive to advanced multimodal
treatment [6,7,13,14]. Patients with MYCN non-amplified
metastatic tumors, however, present highly variable outcomes,
but few endpoint predictors have been described for this group.
Currently, the best known prognostic indicator is the age at
which the tumor is diagnosed [7]. Patients younger than 18
months usually have better prognosis, with more than 90% 6-
year event-free survival for patients younger than one year.
Patients older than 18 months, on the other hand, suffer higher
mortality rates and may present less than 25% 6-years event-
free survival [15,16]. Several high-throughput studies have
been made over the last years to understand the biology
underlying this clinical variability, and at least one of them was
aimed exclusively at these metastatic MYCN non-amplified
patients [17]. Despite intensive study, few predictors have been
brought forward, demanding increased efforts to understand
this remarkable disease.
In recent years, the availability of gene expression studies
has allowed novel strategies for understanding cancer biology.
One of such is the use of mutual information models for
inferring the regulatory networks of transcription factors (TFs)
and their transcriptional targets (or regulons) in the gene
expression profile of a given set of samples [18–20]. This
methodology allows the detection of potential causal
relationships between TFs and specific cancer signatures. As
these statistics depend on rather large sample sizes (n>80),
only recently are they being successfully applied in biology
[21–23]. In this paper, we have reconstructed the
neuroblastoma regulatory network in order to find TFs involved
in the transition from primary tumors to highly aggressive bone
marrow metastasis. We have found evidences that MAX is one
of the master regulators of tumor progression, possibly by
being an additional regulatory step for the availability of
MYC:MAX heterodimers to regulate transcription and increase
proliferation. We have also found evidences that MAX plays a
more prominent role in SH-SY5Y cells differentiation than
previously described.
Results
Neuroblastoma regulatory network and master
regulator analysis
Through our regulatory network reconstruction workflow
(Figure 1), we have identified 15,713 targets for 1,363 TFs in
the first reconstructed neuroblastoma regulatory network
(GSE16476), and 4,039 targets for 705 TFs in the second
(GSE3960) (Figure 2). We have found eight master regulators
(MRs) common to both networks (Table S1) using as query an
aggressive neuroblastoma metastatic gene signature. We have
chosen only regulons common to both networks so as to
improve the specificity of our MRs analysis. However, by this
criterion alone, there was still an elevated chance of finding
nonspecific TFs. To overcome this problem, we have used the
metastatic neuroblastoma gene signature to query a healthy
mammary tissue network (GSE10780) [24] and use it as a
positive control to detect MRs that are not tissue-specific to
neuroblastoma. We then re-ran the MR analysis within the two
neuroblastoma networks using as query the meta-PCNA
proliferative gene signature [25]. This last step was performed
in order to exclude MRs that were directly involved with
proliferation. Of the eight MRs common to both networks, only
MAX, TFEC, and ZNF101 remained after these specificity
tests.
Regulon overlap and motif analysis
In order to validate the power of our pipeline for detecting
biologically significant regulons, we have compared the
composition of each regulon across the two neuroblastoma
networks and verified whether their members were enriched
with the binding site motif of its MR. We have found less than
1% overlap in the genes potentially regulated by MAX and
ZNF101 in both networks, and 25% for TFEC. We proceeded
to search for regulatory motifs in the targets sequences
flanking regions. Because there are no available motifs for
TFEC and ZNF101 in public databases, we could only query
for the known MAX motif V$MAX, obtained at the JASPAR
database [26,27]. We have found significant enrichment for V
$MAX motif in both networks (p=0.038), indicating that our
pipeline predicted correctly both MAX regulons, albeit their
different compositions. Although there is no public TFEC motif
available, this transcription factor is a member of the MITF
bHLH family, which is closely related to MAX and MYC families
[28]. Members of these families have similar CACGTG binding
motifs, meaning that we can query the TFEC regulon using V
$MAX motif to determine whether it is regulated by a bHLH
transcription factor. TFEC regulon was significantly enriched
with this motif (p=0.003), suggesting that it is indeed regulated
by a bHLH factor.
Given that the MYC/MAX/MAD network may regulate up to
15% of the human genome [29–31], one would not expect
finding substantial overlap in both networks, particularly when
taking into account the significant genetic heterogeneity across
tumors of the same type, which could greatly affect the
specificity of such an important regulatory system. Taking this
into consideration and the fact that both MAX regulons were
significantly enriched with V$MAX binding motif, we chose to
carry our analysis with this gene. ZNF101 was not analyzed
further because it did not have corresponding probes the
datasets below.
Clinical relevance of MAX and TFEC expression in
neuroblastoma
To access whether MAX and TFEC expression could be
related to patient outcome, we have analyzed the GSE3446
dataset [17]. This dataset consists of expression profiles of
primary tumor biopsies obtained at diagnosis from
neuroblastoma patients who (i) either had relapse after five
years (n=46), (ii) did not present disease progression in the
same period (n=56), and (iii) from tumors obtained at
progression (n=12 + 3 obtained both at diagnosis and relapse).
All patients in this study had untreated metastatic MYCN non-
amplified tumors. 74 of the 102 patients studied at diagnosis
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were considered high risk by COG risk stratification, and the
rest was ranked as intermediate risk. We have found that MAX
expression was significantly higher in patients who did not
present disease setback in five years as opposed to those who
had or were already in relapse (Figure 3), indicating that this
Figure 1.  Schematic representation of the workflow used for reconstructing the neuroblastoma network and searching
for master regulators of a metastatic gene signature.  
doi: 10.1371/journal.pone.0082457.g001
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Figure 2.  The neuroblastoma reconstructed regulatory network.  Principal components of the regulatory networks inferred
using GSE3996 (A) and GSE16476 (B) datasets. Each node represents a regulon, which is named by its regulator transcription
factor. Node sizes are proportional to the number of regulon members, node colors are representative of enrichment significance,
and edges widths are proportional to regulon overlap (using Jaccard similarity).
doi: 10.1371/journal.pone.0082457.g002
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gene plays an important role in disease progression. We did
not find any significant alterations in TFEC expression.
We have also analyzed two neuroblastoma survival cohorts
with gene expression data. In the first cohort (E-TABM-38,
n=130) [32], we have found that lower MAX expression
correlated with decreased patient survival (Figure 4a),
corroborating our previous result. However, this was not the
case with the second cohort (E-MTAB-179, n=478) [33], in
which higher MAX expression significantly correlated with poor
survival (Figure 4b). We could not analyze TFEC because
these studies were made with custom array platforms that did
not contain probes for this gene. This was also the case with
the regulons members themselves, which were poorly
represented in these platforms and could not be analyzed
further. We chose to analyze these genes in other types of
cancers so as to detect if there was a general trend for their
expression which could confirm our previous results with MAX
and shed some light at TFEC. Using the Kaplan-Meier Plotter
web tool [34,35], we have found that higher MAX expression
was associated with improved prognosis in breast cancer
(Figure S1), in lung cancer (Figure S2), and not related to
prognosis in ovarian cancer cohorts (Figure S3). As for TFEC,
we have found association with higher expression of this gene
and improved lung cancer survival (Figure S4). We have not
found associations with TFEC expression in breast and ovarian
cancer outcome (Figures S5 and S6, respectively). Detailed
results from this analysis are presented in Table 1.
Role of MAX and TFEC in SH-SY5Y differentiation
To understand whether the alterations detected previously in
MAX expression could be involved in neuroblastoma cells
differentiation and, as such, provide an explanation to why
there seems to be a correlation with patient outcome, we chose
to study a dataset of neuroblastoma SH-SY5Y cells undergoing
differentiation (GSE9169) [36]. In this study, the authors
differentiated cells by treatment with retinoic acid for 8 days,
with further addition of brain-derived neurotrophic factor
(BDNF) after the 5th day. We have found a significant increase
in MAX expression starting at the 3rd and 5th days, which lasted
until the end of the differentiation protocol (Figure 5). We have
not found any significant alterations in TFEC expression during
the course of this experiment (data not shown).
We have also performed a similar SH-SY5Y differentiation
protocol in our laboratory and quantified MAX protein content
during differentiation. We have found an increased amount of
MAX after the 4th day of experiment (Figure 6), demonstrating
that the changes in mRNA expression are indeed reflected at
protein level in neuroblastoma cells.
Discussion
Neuroblastoma is clinically very heterogenic, and one of the
possible outcomes for this disease is spontaneous tumor
regression [1,2]. There are reported cases of differentiation of
these tumors into benign ganglioneuromas, but the
mechanisms by which this processes can occur are still
unknown [8,37,38]. We have queried our reconstructed
neuroblastoma network with a genetic signature related to
bone marrow metastases, which are considered grim clinical
prognosis for neuroblastoma patients [3,39]. We have
observed that MAX regulon was significantly enriched with
differentially expressed genes, suggesting its role as a master
regulator of the transition from primary tumor to metastasis.
Also, this regulon was not enriched in a healthy control
network, neither involved with a nonspecific proliferative
signature, corroborating that it is related to neuroblastoma-
specific pathways.
MAX expression was significantly altered in three
independent gene expression studies. In the first, we have
observed that neuroblastoma patients who did not present
disease relapse in five years had significant higher levels of
MAX expression than patients who either had or were already
at relapse. Of important note is that only 3 of the 15 patients
studied at relapse were from those included at the beginning of
the study, meaning that we can treat this last group
independently. This result suggests that higher MAX levels are
associated to improved patient prognosis in patients with high
risk, MYCN non-amplified metastatic neuroblastoma.
Corroborating this data, we have analyzed a survival cohort of
neuroblastoma patients and found that individuals with lower
MAX expression had significantly decreased survival rates than
the others. However, we have found the opposite results in a
second neuroblastoma cohort. In this study, patients with
higher MAX expression levels presented lower survival rates
than the rest. It is possible that this incongruence is brought by
the great variability in the two survival cohorts. Patients in
these studies, albeit having mostly MYCN non-amplified
tumors, were sorted across all risk stages and were subject to
different types of therapy, thus making difficult our attempts at
understanding this data. Nevertheless, we have also found
positive association of MAX expression and improved
prognosis in two independent cohorts of breast and lung
cancer patients, corroborating its role in disease progression.
To address whether MAX expression could affect
neuroblastoma by activating a differentiation pathway, we have
analyzed a dataset of MYCN non-amplified neuroblastoma
cells SH-SY5Y subjected to a differentiation protocol. Strikingly,
we have found a peak of MAX expression between the third
and fifth days of differentiation, lasting to the end of the
experiment. This data makes us believe that MAX is one the
late effectors SH-SY5Y differentiation, suggesting that its
expression is implicated in favorable outcomes for MYCN non-
amplified neuroblastoma patients by means of enhancing cell
differentiation and/or impairing proliferation. These results are
further corroborated by the increase of MAX protein levels we
have observed in our SH-SY5Y cells differentiation protocol.
The MYC/MAX/MAD network is a key axis in the cell
decision-making for differentiation and proliferation, and it is
altered in several types of cancer [40–42]. Much has been said
about the oncogenic roles of MYC family genes, but, other than
being the obligatory heterodimer of MYC and MAD families of
proteins, little is known about how variations in MAX
expression can affect cell-cycle progression. In earlier cell
differentiation studies, it was found that MAX expression
remains constant throughout the process [43] (for a review, see
[44] and references therein). One study demonstrates that
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Figure 3.  MAX expression in the GSE3446 patient cohort.  Boxplots representations of patients who did not present relapse in
five years, and patients that either had or were already at relapse, respectively. y-axis represents relative MAX expression
(normalized sample value divided by MAX mean across all samples). Boxplot bars indicate lower and upper quartiles, central bar
indicates mean, whiskers indicate one standard deviation of mean, and box widths are proportional to sample size. Double asterisks
indicates significant differences from the first group (p<0.001, two-tailed pairwise t-tests with Bonferroni correction).
doi: 10.1371/journal.pone.0082457.g003
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Figure 4.  MAX expression and patient survival.  Kaplan-Meier plots of E-TABM-38 (A) and E-MTAB-179 (B) patient cohorts. x-
axis indicates event-free survival time. y-axis represents the percentage of patients event-free survival. The red line represents
patients with lower MAX expression, and the blue line, patients with higher MAX expression. Crosses mark censored data.
doi: 10.1371/journal.pone.0082457.g004
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MAX -/- mice are subject to early embryonic lethality [45],
indicating that this gene plays a vital role in development.
These results suggest that this gene is indispensable to
differentiation and proliferation processes, albeit only as an
accessory part of its network. Lindeman and colleagues [46],
however, have elegantly demonstrated that MAX has a more
active role decreasing the size and frequency of tumors when
overexpressed in lymphoma susceptible mice. In their study,
authors have transfected mice lineages with two different MAX
transgenes. They observed that both strains presented
impaired lymphoproliferation and delayed tumor onset when
co-expressed with a highly active MYC transgene.
Interestingly, the authors noted that the MAX transgene with
higher activity presented more pronounced tumor impairing
capacity than the less active one, indicating that MAX has
indeed tumor suppressing properties, and that the latter may
be dose-dependent. These results are in accordance to related
papers that link MAX overexpression with increased
differentiation in other cell lines [47,48], and particularly, the
work of Peverali and colleagues using neuroblastoma cells
[49]. This author demonstrated that retinoic acid-treatment in
SK-N-BE neuroblastoma cells overexpressing MAX induced
differentiation more than twice as fast as with retinoic acid
alone. Curiously, this cells are MYCN amplified, suggesting
that MAX expression is sufficient to revert proliferation even in
more aggressive neuroblastoma cell variants.
Because these studies were made using overexpression
techniques, one may argue that they are not accurate
reflections of biological processes occurring at more
physiological conditions. The only currently known association
with MAX and tumor biology in humans comes from studies of
pheochromocytoma and paraganglioma patients. Several
independent research centers have observed correlations
regarding possible inactivating mutations in MAX exons and
the appearance of these tumors [50–54]. These results further
suggest the tumor suppressing properties of MAX. To our
notice, the spontaneous increase in MAX expression during
SH-SY5Y retinoic acid-induced differentiation was the first of
this kind to be reported, and leads us to question whether this
gene could have a more prominent role in neuroblastoma
progression and neuronal cells progenitors development than
previously described.
It is known that the MAX:MYC heterodimer induces cell
proliferation by interacting with the TRRAP complex and
histone acetyltransferases to transcriptionally activate cell cycle
Table 1. Survival statistics for MAX and TFEC in other type
of cancers.
Gene Cancer Hazard Ratio p value n
MAX Breast 0.75 1.E-06 2,878
 Lung 0.45 1.E-14 1,404
 Ovarian ns ns 1,171
TFEC Breast ns ns 2,878
 Lung 0.57 1.E-09 1,404
 Ovarian ns ns 1,171
doi: 10.1371/journal.pone.0082457.t001
activators such as cyclins, and possibly repressing cell cycle
inhibitors [55–57]. The MAX:MAD/MNT complex and the MAX
homodimer, on the other hand, are proliferation repressors and
inducers of terminal differentiation in various cell types [58–60].
The heterodimerization of MYC and MAX is preferential
because the stabilization of their bHLH is thermodynamically
more favorable than that of MAD and MNT with MAX [61].
Being the limiting factor of its network, one possible
mechanism for how changes in MAX expression can interfere
directly with proliferation/differentiation fate in cell is by
regulating the amount of MYC that can activate gene
expression. Lower quantities of MAX would bind preferentially
with MYC and change the network balance towards
proliferation. As MAX levels rise, all the available MYC binding
sites would be occupied and more MAD:MAX, MNT:MAX and
MAX:MAX dimers would be formed, switching the balance
towards differentiation (Figure 7). In MYCN amplified tumors, a
larger fraction of MAX would be used to form pro-proliferative
MAX:MYCN heterodimers, explaining how these cells are more
resistant to exit division [47]. In line with this, there have been
studies with compounds that are able to disrupt the MYC:MAX
complex in order to decrease malignancy [62,63]. Of particular
relevance is the recent work of Montagne and colleagues [64],
that used MAX bHLH as a protein transduction domain for
decreasing MYC availability to interact with MAX, thus
impairing proliferation in HeLa cells. These results demonstrate
MAX capacity of directly interfering with MYC activity. Put
together, this data bring MAX forward as a central player in its
network, and urge us to dedicate more research in this
intriguing subject.
There are questions made during this work that must be
addressed in the near future. It would be interesting to compare
whether MAX levels are different in stage 4s patients in order
to clinically corroborate our findings with SH-SY5Y cells. There
is also the putative role of ZNF101 and TFEC, which were
pointed as master regulators but could not be implicated in this
disease by means of their expression. We have found an
indication that the latter is associated in lung cancer outcome,
suggesting its importance may be greater than previously
thought. The accurate roles of these genes in neuroblastoma
progression are an open question and additional assays are
needed to address this matter.
Conclusions
We have found evidences that MAX expression plays a role
in neuroblastoma biology that has not been previously
described, possibly as an additional regulator of the availability
of MYC:MAX heterodimers and the balance of proliferation/
differentiation. Our analyses also point that this gene may be
used as a candidate predictor for positive clinical outcomes of
MYCN non-amplified neuroblastoma patients. We have
detected significant associations between higher MAX
expression and improved survival rates for breast and lung
cancer patients, suggesting that the clinical predictor potential
can also be extended to other types of tumors. Lastly, we have
observed that MAX expression was significantly altered during
SH-SY5Y retinoic acid-induced differentiation, providing a
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mechanism for which this gene could be linked to tumor
progression.
Materials and Methods
Neuroblastoma regulatory network reconstruction and
master regulator analysis
The neuroblastoma regulatory network was reconstructed
and plotted using, respectively, the RTN [65] and RedeR [66]
packages for R Statistical Computing, available at
Bioconductor [67]. This analysis uses the information-theoretic
content (i.e. mutual information) of the gene expression profile
for inferring relevant pairwise interactions among genes.
Regulatory networks were reconstructed from the
neuroblastoma biopsies datasets GSE16476 [68] and
GSE3960 [69]. Human transcription factors were gathered from
the Animal Transcription Factor Database [70]. Master
regulator analyses were made using as query a genetic
Figure 5.  MAX expression in SH-SY5Y cells differentiation.  x-axis indicates the time course of differentiation (times preceded
by “b” indicate the addition of BDNF in the experimental protocol). y-axis indicates relative MAX expression (normalized sample
value divided by MAX mean across all samples). Triple asterisks indicates statistically significant differences from the first three
days (p<10-5, two-tailed pairwise t-tests with BH correction).
doi: 10.1371/journal.pone.0082457.g005
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signature obtained from aggressive metastases. For assessing
this metastatic signature, we have used Limma R package [71]
on the GSE25623 dataset [72] in order to discover differentially
expressed genes between neuroblastoma primary tumors and
bone marrow metastases (for a schematic description of this
workflow, we once again refer the reader to Figure 1). Master
regulators DNA-binding motifs were searched using the FIMO
tool for transcription factor binding site prediction [73]. We have
considered target genes only those that had at least one motif
occurrence in their flanking regions (either 2.5 Kb up and
downstream from the gene start codon [74]). To assess
whether regulons were significantly enriched with genes
regulated by its transcription factor, we verified if our prediction
was significantly higher than randomly sampling all human
genes 100,000 times using regulon-sized samples. Statistical
significance was calculated using one-tailed z-tests.
SH-SY5Y differentiation and Western blot analysis
Human neuroblastoma SH-SY5Y cells were obtained from
the American Type Culture Collection (ATCC, Rockville, MD).
Cells were cultivated using Dulbecco's Modified Eagle's
Medium supplemented with 10% heat-inactivated fetal bovine
serum, L-glutamine (2mM), and 0.28 mg/ml of gentamycin
sulfate in a 5% CO2 humidified incubator at 37°C.
Differentiation protocol consisted in reducing fetal bovine
serum concentration to 1% and adding retinoic acid (10µM)
during 10 days. The culture medium was replaced every three
days. Cells were grown in 6-well cluster dishes.
Figure 6.  MAX immunocontent in differentiating SH-SY5Y neuroblastoma cells treated with retinoic acid for 10
days.  Asterisks indicate statistically significant (p<10-3) changes in the MAX/β-actin ratio in relation to the first day.
doi: 10.1371/journal.pone.0082457.g006
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Proteins (20µg) were separated using SDS-PAGE – 10%
(w/v) acrylamide, 0.275% (w/v) bisacrylamide gels – and
electrotransferred onto nitrocellulose membranes. Membranes
were then incubated in Tris-buffered saline Tween-20 [TBS-T;
20 mM Tris–HCl, pH 7.5, 137 mM NaCl, 0.05% (v/v) Tween 20]
for 1h at room temperature. Subsequently, membranes were
incubated for 12h with polyclonal rabbit anti-MAX (1:1.000
dilution; Cell Signaling). After washing in TBST, blots were
incubated with rabbit peroxidase-linked anti-immunoglobulin G
(IgG) antibodies (1:10.000 dilution) for 1.5h at room
temperature. Chemiluminescent bands were detected, and
densitometric analysis was performed by Image-J® software.
All analyses were performed in triplicate.
Figure 7.  Schematic representation of MAX expression in neuroblastoma cell behavior.  Cells with lower MAX concentration
preferentially form pro-proliferative MYC:MAX heterodimers, leading to increased proliferation and de-differentiation (A). With higher
MAX levels, there is no more free MYC available and more MAD:MAX heterodimers and MAX homodimers are formed, shifting
balance towards differentiation (B).
doi: 10.1371/journal.pone.0082457.g007
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Statistical analyses
Unless stated otherwise, all statistical analyses were made
using two-tailed t-tests. Pairwise t-tests were made with
Bonferroni and BH p-value corrections when more than two
groups were analyzed. The latter was used when testing for
more than four groups. Survival curves for gene expression
were drawn using Kaplan-Meier plot and tested with Cox
proportional hazards model using the Survival [75] and
Survcomp [76] packages for R statistical computing. The best
cutoff for samples split was chosen by plotting all percentiles of
gene expression between the upper and lower quartiles and
selecting the best performing threshold. For breast, lung and
ovarian cancers, statistics were made using the Kaplan-Meier
Plotter web tool. Parameters used in all analyses were auto
select split cutoff and only the JetSet best probes were
selected [77]. All gene expression profiles used in this paper
were obtained from Gene Expression Omnibus and
ArrayExpress public databases.
Supporting Information
Figure S1.  Kaplan-Meier plot of the 2012 breast cancer
patient cohort available at the Kaplan-Meier Plotter web
tool. x-axis indicates event-free survival time. y-axis represents
the percentage of patients event-free survival. The black line
represents patients with lower MAX expression, and the red
line, patients with higher MAX expression. Crosses mark
censored data.
(TIFF)
Figure S2.  Kaplan-Meier plot of the unified lung cancer
patient cohort available at the Kaplan-Meier Plotter web
tool. x-axis indicates event-free survival time. y-axis represents
the percentage of patients event-free survival. The black line
represents patients with lower MAX expression, and the red
line, patients with higher MAX expression. Crosses mark
censored data.
(TIFF)
Figure S3.  Kaplan-Meier plot of the 2013 ovarian cancer
patient cohort available at the Kaplan-Meier Plotter web
tool. x-axis indicates event-free survival time. y-axis represents
the percentage of patients event-free survival. The black line
represents patients with lower MAX expression, and the red
line, patients with higher MAX expression. Crosses mark
censored data.
(TIFF)
Figure S4.  Kaplan-Meier plot of the 2012 breast cancer
patient cohort available at the Kaplan-Meier Plotter web
tool. x-axis indicates event-free survival time. y-axis represents
the percentage of patients event-free survival. The black line
represents patients with lower TFEC expression, and the red
line, patients with higher TFEC expression. Crosses mark
censored data.
(TIFF)
Figure S5.  Kaplan-Meier plot of the lung cancer patient
cohort available at the Kaplan-Meier Plotter web tool. x-axis
indicates event-free survival time. y-axis represents the
percentage of patients event-free survival. The black line
represents patients with lower TFEC expression, and the red
line, patients with higher TFEC expression. Crosses mark
censored data.
(TIFF)
Figure S6.  Kaplan-Meier plot of the 2013 ovarian cancer
patient cohort available at the Kaplan-Meier Plotter web
tool. x-axis indicates event-free survival time. y-axis represents
the percentage of patients event-free survival. The black line
represents patients with lower TFEC expression, and the red
line, patients with higher TFEC expression. Crosses mark
censored data.
(TIFF)
Table S1.  Overview of all Master Regulators found in our
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